Kitaadachi-gun, Japan Clinical Trials

A listing of Kitaadachi-gun, Japan clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
Efficacy & Safety of TD-1473 in Ulcerative Colitis

A Phase 2b/3 set of studies to evaluate the efficacy and safety of induction and maintenance therapy with TD-1473 in subjects with moderately-to-severely active ulcerative colitis with up to 60 weeks of treatment.

immunomodulators
aminosalicylates
corticosteroids
Theravance Biopharma Investigational Site
 (3.0 away) Contact site
  • 75 views
  • 28 Jan, 2021
  • +202 other locations
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease.

abdominal pain
endoscopy
colitis
ileitis
fistulising crohn's disease
Saitama Medical Center
 (8.6 away) Contact site
  • 792 views
  • 18 Jun, 2021
  • +796 other locations
A Multicenter Randomized Double-Blind Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the appropriate induction dose of risankizumab for further evaluation in Sub-Study 2. The objective of Sub-Study 2 is to …

remission
Tokito Clinic /ID# 164253
 (9.9 away) Contact site
  • 604 views
  • 16 Jun, 2021
  • +772 other locations
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis (UC).

medical therapy
Japan Community Health Care Organization Saitama Medical Center
 (8.6 away) Contact site
  • 226 views
  • 16 Jun, 2021
  • +519 other locations
Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease

The primary objective of the study is to determine if treatment with high-dose aflibercept (HD) at intervals of 12 or 16 weeks provides non-inferior best corrected visual acuity (BCVA) compared to aflibercept dosed every 8 weeks. The secondary objectives of the study are as follows: To determine the effect of …

diabetic macular edema
diabetic eye disease
retinopathy
corrected visual acuity
visual impairment
Regeneron Study Site
 (7.5 away) Contact site
  • 17 views
  • 14 May, 2021
  • +199 other locations
TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study

A 3-Year Multi-Center, Long-Term Safety (LTS) Study to Evaluate the Safety and Tolerability of TD-1473 in Subjects with Ulcerative Colitis who have participated in the Maintenance Study of Protocol 0157

remission
Theravance Biopharma Investigational Site
 (3.0 away) Contact site
  • 7 views
  • 28 Jan, 2021
  • +158 other locations
Efficacy and Safety of MK-1654 in Infants (MK-1654-004)

The primary objectives of this phase 2b/3 double-blind, randomized, placebo-controlled study are to evaluate the efficacy and safety of MK-1654 in healthy pre-term and full-term infants. It is hypothesized that MK-1654 will reduce the incidence of respiratory syncytial virus (RSV)-associated medically attended lower respiratory infection (MALRI) from Days 1 through …

Saitama City Hospital ( Site 3055)
 (8.1 away) Contact site
  • 0 views
  • 19 Jun, 2021
  • +18 other locations
A Phase II/III Study of Sargramostim

This is a randomized, placebo-controlled, double-blind, group comparison, multicenter study to evaluate the efficacy and safety of inhalation administration of sargramostim for 5 days, in principle (up to 10 days) as Add-on treatment to the standard treatment in COVID-19 patients.

Japanese Red Cross Society Saitama Red Cross Hospital
 (9.6 away) Contact site
  • 0 views
  • 16 May, 2021
  • +6 other locations